B
MLYS icon

Braidwell’s Mineralys Therapeutics MLYS Stock Holding History

Braidwell’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,147,154
Closed -$14.8M – 82
2024
Q1 		$14.8M Sell
1,147,154
-876,746
-43% -$10.8M 0.48% 56
2023
Q4 		$17.4M Hold
2,023,900
– – 0.64% 45
2023
Q3 		$19.2M Buy
2,023,900
+1,473,600
+268% +$19.2M 0.61% 54
2023
Q2 		$9.38M Hold
550,300
– – 0.31% 72
2023
Q1 		$8.62M Buy
+550,300
New +$9.26M 0.28% 69

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Braidwell's MLYS Position: Q2 2024 in Review

Braidwell sold out of Mineralys Therapeutics (MLYS) in Q2 2024, closing a stake of 1,147,154 shares — an estimated $14.8M sold.

Braidwell first reported a position in MLYS in Q1 2023 and held it in 5 quarters. The position peaked at $19.2M in Q3 2023. 94 funds tracked by Wall St. Rank hold MLYS as of Q2 2024.

  • Braidwell reported no remaining Mineralys Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Braidwell sold 1,147,154 Mineralys Therapeutics shares in Q2 2024, an estimated $14.8M.
  • Braidwell first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 5 quarters.
  • Braidwell's Mineralys Therapeutics position peaked at $19.2M in Q3 2023.
  • 94 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2024.

Based on Braidwell's 13F filing for Q2 2024, filed 14 Aug 2024.